Anthony Liwa

Anthony Liwa

Auto-generated profile, based on publicly available information

Anthony Liwa

Department of Clinical Pharmacology, Catholic University of Health and Allied Sciences, P.O. Box 1464, Mwanza, Tanzania

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2017 in International Journal of Hypertension
Verified
Journal Article
Open access
PDF file
ALAnthony Liwa
Anthony Liwa
RRRebecca Roediger
Rebecca Roediger
HJHyasinta Jaka
Hyasinta Jaka
ABAmina Bougaila
Amina Bougaila
LSLuke R. Smart
Luke R. Smart
RPRobert Peck
Robert Peck
Background. Hypertension is increasingly common in sub-Saharan Africa where traditional medicine use is also common. We conducted a hospital-based, mixed-methods study to determine prevalence, pattern, and correlates of herbal and alternative medicine use in Tanzanian adults hospitalized with hypertension. Methods. A standardized questionnaire was administered. In-depth interviews were performed on a subset of participants. Factors associated with herbal medicine use were determined by logistic regression. The association between traditional medicine uses and allopathic medication adherence was determined using ordinal logistic regression. Qualitative data were analyzed according to grounded theory. Results. Of 213 adults enrolled, 52 (24.4%) reported using herbs during the previous month and 47 (22.1%) reported concurrent use of herbs and allopathic medicines. Lower educational level, nonprofessional employment, and lack of health insurance were significantly associated with herbal medicine use. Alternative medicines use was not associated with lower medication adherence. Qualitative interviews identified several important themes including reasons for herbal medicine use. Conclusion. The use of traditional medicines is very common among patients with hypertension. Adults from low socioeconomic status, those with misunderstandings about hypertension, and those without health insurance were more likely to take herbs. Open, nonjudgmental communication between healthcare workers and patients regarding use of traditional medicines must be encouraged in Africa.

5 September 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
KMKarol J Marwa
Karol J Marwa
ALAnthony C Liwa
Anthony C Liwa
EKEveline T Konje
Eveline T Konje
SMStanley Mwita
Stanley Mwita
EKErasmus Kamugisha
Erasmus Kamugisha
GSGöte Swedberg
Göte Swedberg
Therapeutic efficacy of artemether-lumefantrine is highly dependent on adequate systemic exposure to the partner drug lumefantrine particularly day 7 lumefantrine plasma concentration. There has been contradicting findings on the role of the cut-off values in predicting treatment outcomes among malaria patients in malaria endemic regions. This study assesses the day 3 and 7 lumefantrine plasma concentrations including related determinant factors and their influence on treatment outcomes among treated Tanzanian children and adults in uncontrolled conditions (real life condition). Data was nested from an efficacy study employing the WHO protocol, 2015 for monitoring antimalarial drug efficacy. Lumefantrine plasma concentration was measured by high performance liquid chromatography with ultraviolet (HPLC-UV). Lumefantrine plasma concentrations below 175ng/ml and 200ng/ml on day 3 and 7 did not affect adequate clinical and parasitological response (ACPR) and recurrence of infection (p = 0.428 and 0.239 respectively). Age and baseline parasitemia were not associated to day 3 median lumefantrine plasma concentrations (p = 0.08 and 0.31 respectively) and day 7 lumefantrine plasma concentrations (p = 0.07 and 0.41 respectively). However, the day 3 and day 7 lumefantrine plasma concentrations were significantly higher in males compared to females (p = 0.03 and 0.042 respectively). Lumefantrine plasma concentrations below cut-off points (175ng/ml and 200ng/ml) on day 3 and 7 did not influence treatment outcomes.

1 February 2025 in Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
PDF file
DKDeogratias Mwombeki Katabalo
Deogratias Mwombeki Katabalo
SMStanley Mwita
Stanley Mwita
ALAntony Cuthbert Liwa
Antony Cuthbert Liwa
BKBenson Richard Kidenya
Benson Richard Kidenya
KSKristin Schroeder
Kristin Schroeder
Background: Pharmacogenomics holds significant promise in improving the efficacy and safety of chemotherapy for childhood cancers. However, the field remains underexplored in Africa, where high genetic diversity and substantial disease burdens, including cancers, create unique challenges. This review investigates the current state of pharmacogenomics research in childhood cancer chemotherapies across Africa, focusing on genetic variations influencing chemotherapy efficacy and adverse drug reactions. It also highlights critical gaps, such as limited infrastructure and insufficient healthcare worker knowledge, and emphasizes the importance of capacity-building initiatives in the region. Methods: A scoping review was conducted encompassing studies published up to September 2024 that examined pharmacogenomic variations associated with chemotherapies in childhood cancer patients across Africa. The review included laboratory genetic analyses and surveys assessing healthcare workers’ knowledge, attitudes, and perceptions regarding pharmacogenomics, particularly in the context of pediatric oncology. Results: A total of 12 genes were identified across eight studies, including TPMT, CYP3A5, MDR1, MAPT, NUDT15, ITPA, IMPDH1, SLC29A1, SLC28A2, SLC28A3, ABCC4, and MTHFR. The most studied genes were TPMT and CYP3A5, which are involved in the metabolism of 6-mercaptopurine (6-MP) and vincristine, respectively. These studies spanned five African countries, including Kenya, Egypt, Zimbabwe, Nigeria, Tunisia, and Libya, and focused primarily on childhood cancers, particularly acute lymphoblastic leukemia. Chemotherapies frequently studied were 6-MP (reported in five studies), vincristine, cyclophosphamide, and methotrexate. Knowledge of pharmacogenomics among healthcare workers in Africa remains low, though a positive attitude towards its clinical applications was observed. Conclusion: Pharmacogenomic variants, such as TPMT*3A, 3C, and CYP3A53, *6, significantly impact drug metabolism in African children with cancer. However, research remains regionally limited, and gaps in infrastructure and healthcare worker training persist. Expanding research efforts and improving pharmacogenomics capacity through pharmacist training and capacity-building initiatives are essential to advancing personalized medicine in Africa, ultimately improving treatment outcomes for pediatric cancer patients.

1 January 2026 in Drug, Healthcare and Patient Safety
Verified
Journal Article
Open access
DKDeogratias Mwombeki Katabalo
Deogratias Mwombeki Katabalo
ENEsther Njile
Esther Njile
BKBenson Kidenya
Benson Kidenya
ALAnthony Liwa
Anthony Liwa
KSKristin Schroeder
Kristin Schroeder
Background: Chemotherapy remains the cornerstone of pediatric cancer treatment, yet its cytotoxic nature often results in chemotherapy-induced toxicities, adverse effects arising from damage to healthy, rapidly dividing cells. Data describing these toxicities from the patient and caregiver perspective are scarce in sub-Saharan Africa. This study assessed the types, severity, and determinants of Chemotherapy-Induced Toxicities among pediatric cancer patients in Tanzania. Methodology: A descriptive cross-sectional study was conducted over six months at Bugando Medical Center. Pediatric patients aged birth to 18 years receiving chemotherapy were enrolled. Toxicities were assessed using a locally validated, Swahili-translated version of the Pediatric Patient-Reported Outcomes Common Terminology Criteria for Adverse Events tool. Children aged ≥ 7 years self-reported their symptoms, while caregivers provided proxy reports for younger children and those who can not express themselves. Associations between chemotherapy-induced toxicities and demographic or treatment variables were analysed using multivariate logistic regression to adjust for potential confounding factors or variables (p < 0.05). Results: Of 120 participants (55.8% male), all experienced at least one Chemotherapy-Induced Toxicity, with a mean of five per participant. The most common toxicities were alopecia (82.5%), taste changes (74.2%), vomiting (44.2%), and nausea (35%). Most events were mild (grade 1). In multivariable analysis, cancer classification was the only significant predictor of toxicity, with solid tumors showing higher odds of ≥ Grade 2 Chemotherapy-induced toxicities compared with hematologic cancers (AOR = 7.42, p = 0.047). Other factors showed no statistically significant associations. Conclusion: Chemotherapy-induced toxicities were frequent, with most children experiencing multiple symptoms across organ systems. Cancer classification was the only factor significantly associated with higher-grade toxicities. Integrating child-and caregiverreported outcome measures into pediatric oncology practice could enhance early identification of toxicities, support timely management, and inform national strategies to improve treatment safety and quality of life for children with cancer in Tanzania.

2 September 2026 in AlQalam Journal of Medical and Applied Sciences
Verified
Journal Article
Open access
PDF file
MJMasanyiwa James
Masanyiwa James
ALAnthony Liwa
Anthony Liwa
DBDeogratius Bintabara
Deogratius Bintabara
PSPhilip Sasi
Philip Sasi
Neonatal sepsis remains a major cause of morbidity and mortality, particularly in low-resource settings. Gentamicin is widely used for treatment; however, its narrow therapeutic index and variable neonatal pharmacokinetics increase the risk of accumulation and toxicity. Therapeutic drug monitoring is rarely available in Tanzania. Identifying factors associated with elevated gentamicin concentrations may support safer antibiotic use where therapeutic drug monitoring is unavailable. This study aimed to identify factors associated with elevated gentamicin trough concentrations among term neonates receiving once-daily intravenous gentamicin. This sub-study was nested within a prospective observational cohort evaluating the pharmacokinetics and safety of once-daily intravenous gentamicin at doses of 4 mg/kg and 5 mg/kg among term neonates with sepsis. A total of 250 neonates receiving gentamicin were included. Trough concentrations were measured at steady state, five minutes before the fourth dose. An elevated trough concentration was defined as >2 µg/mL. Factors associated with elevated trough concentrations were assessed using multivariable logistic regression, with adjusted odds ratios and 95% confidence intervals. Elevated trough concentrations occurred in 27.2% of neonates. Independent factors associated with elevated trough concentrations included age <7 days (adjusted odds ratio, 4.41; 95% confidence interval, 2.16–8.99), weight 100 µmol/L within the laboratory reference range of 44.22 - 132.63 µmol/L) (adjusted odds ratio, 2.21; 95% confidence interval, 1.03–4.73). More than one-quarter of neonates receiving once-daily gentamicin had elevated trough concentrations. Clinical and dosing-related factors may help identify neonates at risk of gentamicin accumulation and support safer antibiotic use where therapeutic drug monitoring is unavailable.

14 September 2026 in Attahadi Medical Journal
Verified
Journal Article
Open access
PDF file
MJMasanyiwa James
Masanyiwa James
ALAnthony Liwa
Anthony Liwa
DBDeogratius Bintabara
Deogratius Bintabara
PKPeter Kunambi
Peter Kunambi
PSPhilip Sasi
Philip Sasi
Neonatal sepsis remains a major cause of newborn morbidity and mortality in resource-limited settings, where gentamicin is widely used as empirical therapy. In Tanzania, once-daily gentamicin (4–5 mg/kg) is recommended, but the 5 mg/kg regimen is commonly used without routine therapeutic drug monitoring (TDM), raising concerns about nephrotoxicity and ototoxicity. Although the 4 mg/kg once-daily regimen has generally been associated with a lower risk of aminoglycoside-related toxicity than higher-dose regimens, its use in Tanzania remains limited, with the 5 mg/kg regimen more commonly employed. This variation between international evidence and local prescribing practice highlights the importance of evaluating whether the lower-dose regimen may offer a safer therapeutic option for Tanzanian neonates. The growing recognition of medication-related kidney injury in children further highlights the need for safer antimicrobial strategies. However, local evidence comparing the 5 mg/kg and 4 mg/kg regimens remains limited. This study compared the renal and auditory safety of these regimens in term neonates. This prospective observational cohort study included 375 term neonates receiving gentamicin 5 mg/kg (n=125), gentamicin 4 mg/kg (n=125), or ceftriaxone/cefotaxime (n=125). Renal function was assessed using serum creatinine and urinary kidney injury molecule-1 (uKIM-1), while auditory function was evaluated using automated auditory brainstem response (AABR). Nephrotoxicity was defined using kidney disease: Improving Global Outcomes (KDIGO) criteria and ototoxicity as ≥20 dB AABR threshold increase from baseline. Acute kidney injury (AKI) was more frequent and severe in the 5 mg/kg group, with stage I, II, and III AKI occurring in 35.2%, 14.4%, and 1.6%, respectively. The 4 mg/kg group had 2.4% stage I AKI with no stage II/III cases, while no AKI occurred in the comparison group (p<0.001). Ototoxicity occurred in 4.0% receiving 5 mg/kg, with no cases in other groups (p<0.05). The 5 mg/kg regimen was associated with greater renal and auditory toxicity than 4 mg/kg, supporting lower-dose strategies where TDM is unavailable.